CA3217207A1 - Method of optimizing a filling recipe for a drug container - Google Patents

Method of optimizing a filling recipe for a drug container Download PDF

Info

Publication number: CA3217207A1
Authority: CA; Canada
Prior art keywords: degrees; vial; pump; fill; setting
Prior art date: 2021-05-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CA3217207A

Other languages

English (en)

French (fr)

Inventor

Devrishi GOSWAMI

Jun Zhang

Deirdre PIEDMONTE

Vikashni PADMAKUMAR

David Le

Maria Raquel Santos

Wei Qi

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Amgen Inc

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2021-05-21

Filing date

2022-05-19

Publication date

2022-11-24

2022-05-19 Application filed by Amgen Inc filed Critical Amgen Inc

2022-11-24 Publication of CA3217207A1 publication Critical patent/CA3217207A1/en

Status Pending legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 125
239000003814 drug Substances 0.000 title description 13
229940079593 drug Drugs 0.000 title description 7
230000008569 process Effects 0.000 claims abstract description 47
239000000825 pharmaceutical preparation Substances 0.000 claims description 77
229940126534 drug product Drugs 0.000 claims description 75
238000004519 manufacturing process Methods 0.000 claims description 49
239000000203 mixture Substances 0.000 claims description 13
238000009472 formulation Methods 0.000 claims description 12
230000002572 peristaltic effect Effects 0.000 claims description 12
238000012544 monitoring process Methods 0.000 claims description 5
229940126586 small molecule drug Drugs 0.000 claims description 5
229940125385 biologic drug Drugs 0.000 claims description 4
229950000128 lumiliximab Drugs 0.000 description 58
102000004169 proteins and genes Human genes 0.000 description 51
108090000623 proteins and genes Proteins 0.000 description 51
239000000945 filler Substances 0.000 description 21
238000005457 optimization Methods 0.000 description 16
102000005962 receptors Human genes 0.000 description 16
108020003175 receptors Proteins 0.000 description 16
108010074604 Epoetin Alfa Proteins 0.000 description 9
102100034980 ICOS ligand Human genes 0.000 description 8
229960003388 epoetin alfa Drugs 0.000 description 8
-1 mAb Proteins 0.000 description 8
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 7
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 7
102000002265 Human Growth Hormone Human genes 0.000 description 6
230000010437 erythropoiesis Effects 0.000 description 6
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 6
102000004196 processed proteins & peptides Human genes 0.000 description 6
108090000765 processed proteins & peptides Proteins 0.000 description 6
102000003951 Erythropoietin Human genes 0.000 description 5
108090000394 Erythropoietin Proteins 0.000 description 5
108010075944 Erythropoietin Receptors Proteins 0.000 description 5
102100036509 Erythropoietin receptor Human genes 0.000 description 5
102100021866 Hepatocyte growth factor Human genes 0.000 description 5
101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 5
229960004579 epoetin beta Drugs 0.000 description 5
229940105423 erythropoietin Drugs 0.000 description 5
229960001972 panitumumab Drugs 0.000 description 5
239000004033 plastic Substances 0.000 description 5
229920003023 plastic Polymers 0.000 description 5
230000004936 stimulating effect Effects 0.000 description 5
108010029961 Filgrastim Proteins 0.000 description 4
101001019455 Homo sapiens ICOS ligand Proteins 0.000 description 4
108010000521 Human Growth Hormone Proteins 0.000 description 4
239000000854 Human Growth Hormone Substances 0.000 description 4
101710093458 ICOS ligand Proteins 0.000 description 4
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
239000003173 antianemic agent Substances 0.000 description 4
108010002601 epoetin beta Proteins 0.000 description 4
108010067416 epoetin delta Proteins 0.000 description 4
229950002109 epoetin delta Drugs 0.000 description 4
108010081679 epoetin theta Proteins 0.000 description 4
229950008826 epoetin theta Drugs 0.000 description 4
108010030868 epoetin zeta Proteins 0.000 description 4
229950005185 epoetin zeta Drugs 0.000 description 4
229940125367 erythropoiesis stimulating agent Drugs 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
238000005429 filling process Methods 0.000 description 4
239000007788 liquid Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
ZJNLYGOUHDJHMG-UHFFFAOYSA-N 1-n,4-n-bis(5-methylhexan-2-yl)benzene-1,4-diamine Chemical compound CC(C)CCC(C)NC1=CC=C(NC(C)CCC(C)C)C=C1 ZJNLYGOUHDJHMG-UHFFFAOYSA-N 0.000 description 3
108010008165 Etanercept Proteins 0.000 description 3
102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 3
102100039939 Growth/differentiation factor 8 Human genes 0.000 description 3
102000038455 IGF Type 1 Receptor Human genes 0.000 description 3
108010031794 IGF Type 1 Receptor Proteins 0.000 description 3
108090000445 Parathyroid hormone Proteins 0.000 description 3
102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 3
108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 3
102000014128 RANK Ligand Human genes 0.000 description 3
108010025832 RANK Ligand Proteins 0.000 description 3
102100034196 Thrombopoietin receptor Human genes 0.000 description 3
102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 description 3
230000027455 binding Effects 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
229960004177 filgrastim Drugs 0.000 description 3
102000044389 human CD22 Human genes 0.000 description 3
229940071846 neulasta Drugs 0.000 description 3
229940029345 neupogen Drugs 0.000 description 3
108010044644 pegfilgrastim Proteins 0.000 description 3
229940127557 pharmaceutical product Drugs 0.000 description 3
108010017584 romiplostim Proteins 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
102100034608 Angiopoietin-2 Human genes 0.000 description 2
102100038080 B-cell receptor CD22 Human genes 0.000 description 2
101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 2
102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 2
108010019673 Darbepoetin alfa Proteins 0.000 description 2
108091006020 Fc-tagged proteins Proteins 0.000 description 2
102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 description 2
101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 2
238000012369 In process control Methods 0.000 description 2
102000019223 Interleukin-1 receptor Human genes 0.000 description 2
108050006617 Interleukin-1 receptor Proteins 0.000 description 2
102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 2
102000010787 Interleukin-4 Receptors Human genes 0.000 description 2
108010038486 Interleukin-4 Receptors Proteins 0.000 description 2
102000005741 Metalloproteases Human genes 0.000 description 2
108010006035 Metalloproteases Proteins 0.000 description 2
108010056852 Myostatin Proteins 0.000 description 2
102100036893 Parathyroid hormone Human genes 0.000 description 2
108020004459 Small interfering RNA Proteins 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
108700002718 TACI receptor-IgG Fc fragment fusion Proteins 0.000 description 2
101710148535 Thrombopoietin receptor Proteins 0.000 description 2
102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 2
102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 2
108010023082 activin A Proteins 0.000 description 2
239000000556 agonist Substances 0.000 description 2
229940115115 aranesp Drugs 0.000 description 2
102000023732 binding proteins Human genes 0.000 description 2
108091008324 binding proteins Proteins 0.000 description 2
229950007296 cantuzumab mertansine Drugs 0.000 description 2
229960003115 certolizumab pegol Drugs 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
VDHAWDNDOKGFTD-MRXNPFEDSA-N cinacalcet Chemical compound N([C@H](C)C=1C2=CC=CC=C2C=CC=1)CCCC1=CC=CC(C(F)(F)F)=C1 VDHAWDNDOKGFTD-MRXNPFEDSA-N 0.000 description 2
238000012777 commercial manufacturing Methods 0.000 description 2
229960002806 daclizumab Drugs 0.000 description 2
229960005029 darbepoetin alfa Drugs 0.000 description 2
229960001251 denosumab Drugs 0.000 description 2
229940073621 enbrel Drugs 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
229940089118 epogen Drugs 0.000 description 2
229950009760 epratuzumab Drugs 0.000 description 2
229960000403 etanercept Drugs 0.000 description 2
239000012530 fluid Substances 0.000 description 2
239000012634 fragment Substances 0.000 description 2
229960003297 gemtuzumab ozogamicin Drugs 0.000 description 2
239000011521 glass Substances 0.000 description 2
229960001743 golimumab Drugs 0.000 description 2
229960001001 ibritumomab tiuxetan Drugs 0.000 description 2
238000010965 in-process control Methods 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
108010010648 interferon alfacon-1 Proteins 0.000 description 2
229960005386 ipilimumab Drugs 0.000 description 2
229910052742 iron Inorganic materials 0.000 description 2
229960000994 lumiracoxib Drugs 0.000 description 2
229950001869 mapatumumab Drugs 0.000 description 2
229940029238 mircera Drugs 0.000 description 2
229960003301 nivolumab Drugs 0.000 description 2
230000000174 oncolytic effect Effects 0.000 description 2
HQQSBEDKMRHYME-UHFFFAOYSA-N pefloxacin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 HQQSBEDKMRHYME-UHFFFAOYSA-N 0.000 description 2
229960001373 pegfilgrastim Drugs 0.000 description 2
229960002087 pertuzumab Drugs 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
108091033319 polynucleotide Proteins 0.000 description 2
102000040430 polynucleotide Human genes 0.000 description 2
239000002157 polynucleotide Substances 0.000 description 2
229940092597 prolia Drugs 0.000 description 2
229960004641 rituximab Drugs 0.000 description 2
229960004532 somatropin Drugs 0.000 description 2
230000009870 specific binding Effects 0.000 description 2
229950008461 talimogene laherparepvec Drugs 0.000 description 2
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
229960005267 tositumomab Drugs 0.000 description 2
102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
229950001212 volociximab Drugs 0.000 description 2
229940014556 xgeva Drugs 0.000 description 2
229950008250 zalutumumab Drugs 0.000 description 2
HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
UHTZABZWCSJMDY-UHFFFAOYSA-N 2-(chloromethyl)oxirane;n,n,n',n'-tetrakis(3-aminopropyl)butane-1,4-diamine Chemical compound ClCC1CO1.NCCCN(CCCN)CCCCN(CCCN)CCCN UHTZABZWCSJMDY-UHFFFAOYSA-N 0.000 description 1
PFWVGKROPKKEDW-UHFFFAOYSA-N 2-[4-[4-(tert-butylcarbamoyl)-2-[(2-chloro-4-cyclopropylphenyl)sulfonylamino]phenoxy]-5-chloro-2-fluorophenyl]acetic acid Chemical compound C=1C=C(C2CC2)C=C(Cl)C=1S(=O)(=O)NC1=CC(C(=O)NC(C)(C)C)=CC=C1OC1=CC(F)=C(CC(O)=O)C=C1Cl PFWVGKROPKKEDW-UHFFFAOYSA-N 0.000 description 1
RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
MZZYGYNZAOVRTG-UHFFFAOYSA-N 2-hydroxy-n-(1h-1,2,4-triazol-5-yl)benzamide Chemical compound OC1=CC=CC=C1C(=O)NC1=NC=NN1 MZZYGYNZAOVRTG-UHFFFAOYSA-N 0.000 description 1
MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 1
ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 1
102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
102000018746 Apelin Human genes 0.000 description 1
108010052412 Apelin Proteins 0.000 description 1
101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 description 1
108010028006 B-Cell Activating Factor Proteins 0.000 description 1
229960005509 CAT-3888 Drugs 0.000 description 1
229940124296 CD52 monoclonal antibody Drugs 0.000 description 1
229940045513 CTLA4 antagonist Drugs 0.000 description 1
101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 1
101100179591 Caenorhabditis elegans ins-22 gene Proteins 0.000 description 1
108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 1
102000014468 Calcitonin Gene-Related Peptide Receptors Human genes 0.000 description 1
108010078311 Calcitonin Gene-Related Peptide Receptors Proteins 0.000 description 1
102000009410 Chemokine receptor Human genes 0.000 description 1
108050000299 Chemokine receptor Proteins 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
108010047041 Complementarity Determining Regions Proteins 0.000 description 1
102100038497 Cytokine receptor-like factor 2 Human genes 0.000 description 1
101710194733 Cytokine receptor-like factor 2 Proteins 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
102000001301 EGF receptor Human genes 0.000 description 1
102100033183 Epithelial membrane protein 1 Human genes 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
102400000322 Glucagon-like peptide 1 Human genes 0.000 description 1
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
101150043052 Hamp gene Proteins 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
101000741445 Homo sapiens Calcitonin Proteins 0.000 description 1
101100118549 Homo sapiens EGFR gene Proteins 0.000 description 1
101000850989 Homo sapiens Epithelial membrane protein 1 Proteins 0.000 description 1
101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
101001010568 Homo sapiens Interleukin-11 Proteins 0.000 description 1
101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 1
101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 description 1
101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 description 1
101000830603 Homo sapiens Tumor necrosis factor ligand superfamily member 11 Proteins 0.000 description 1
101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 1
201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
108010078049 Interferon alpha-2 Proteins 0.000 description 1
108010005716 Interferon beta-1a Proteins 0.000 description 1
102000003996 Interferon-beta Human genes 0.000 description 1
108090000467 Interferon-beta Proteins 0.000 description 1
102000000589 Interleukin-1 Human genes 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 1
102100030694 Interleukin-11 Human genes 0.000 description 1
102000004388 Interleukin-4 Human genes 0.000 description 1
108090000978 Interleukin-4 Proteins 0.000 description 1
239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
102100026261 Metalloproteinase inhibitor 3 Human genes 0.000 description 1
102000048850 Neoplasm Genes Human genes 0.000 description 1
108700019961 Neoplasm Genes Proteins 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
102000003982 Parathyroid hormone Human genes 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
101710180553 Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 description 1
102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 description 1
101710194807 Protective antigen Proteins 0.000 description 1
101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 1
101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 description 1
102100034201 Sclerostin Human genes 0.000 description 1
108050006698 Sclerostin Proteins 0.000 description 1
101710084578 Short neurotoxin 1 Proteins 0.000 description 1
206010041925 Staphylococcal infections Diseases 0.000 description 1
108010039185 Tenecteplase Proteins 0.000 description 1
108010070774 Thrombopoietin Receptors Proteins 0.000 description 1
102100031294 Thymic stromal lymphopoietin Human genes 0.000 description 1
108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 description 1
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
108050006955 Tissue-type plasminogen activator Proteins 0.000 description 1
101710182223 Toxin B Proteins 0.000 description 1
101710182532 Toxin a Proteins 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
229960000446 abciximab Drugs 0.000 description 1
229940119059 actemra Drugs 0.000 description 1
229940099983 activase Drugs 0.000 description 1
230000004913 activation Effects 0.000 description 1
229960002964 adalimumab Drugs 0.000 description 1
229950009084 adecatumumab Drugs 0.000 description 1
229960000548 alemtuzumab Drugs 0.000 description 1
229960003318 alteplase Drugs 0.000 description 1
150000001413 amino acids Chemical group 0.000 description 1
229960004238 anakinra Drugs 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000002691 anti-thymic effect Effects 0.000 description 1
BWVPHIKGXQBZPV-QKFDDRBGSA-N apelin Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N1[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCSC)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(O)=O)CCC1 BWVPHIKGXQBZPV-QKFDDRBGSA-N 0.000 description 1
229950009925 atacicept Drugs 0.000 description 1
229940120638 avastin Drugs 0.000 description 1
229940003504 avonex Drugs 0.000 description 1
229960004669 basiliximab Drugs 0.000 description 1
229960003270 belimumab Drugs 0.000 description 1
238000011021 bench scale process Methods 0.000 description 1
230000008901 benefit Effects 0.000 description 1
229940021459 betaseron Drugs 0.000 description 1
229960000397 bevacizumab Drugs 0.000 description 1
239000003124 biologic agent Substances 0.000 description 1
229950007940 bixalomer Drugs 0.000 description 1
229960003008 blinatumomab Drugs 0.000 description 1
229940101815 blincyto Drugs 0.000 description 1
229950005042 blosozumab Drugs 0.000 description 1
GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
229960001467 bortezomib Drugs 0.000 description 1
229960003735 brodalumab Drugs 0.000 description 1
229940112129 campath Drugs 0.000 description 1
108700001003 carbamylated erythropoietin Proteins 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
229960005395 cetuximab Drugs 0.000 description 1
229940090100 cimzia Drugs 0.000 description 1
229960003315 cinacalcet Drugs 0.000 description 1
229940047120 colony stimulating factors Drugs 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
229950007276 conatumumab Drugs 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
108010084052 continuous erythropoietin receptor activator Proteins 0.000 description 1
230000003413 degradative effect Effects 0.000 description 1
239000000539 dimer Substances 0.000 description 1
238000006471 dimerization reaction Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
FWZTTZUKDVJDCM-CEJAUHOTSA-M disodium;(2r,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol;iron(3+);oxygen(2-);hydroxide;trihydrate Chemical compound O.O.O.[OH-].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[Na+].[Na+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FWZTTZUKDVJDCM-CEJAUHOTSA-M 0.000 description 1
229960002224 eculizumab Drugs 0.000 description 1
229960001776 edrecolomab Drugs 0.000 description 1
229960000284 efalizumab Drugs 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000000694 effects Effects 0.000 description 1
108010090921 epoetin omega Proteins 0.000 description 1
229950008767 epoetin omega Drugs 0.000 description 1
229940082789 erbitux Drugs 0.000 description 1
AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
229960001433 erlotinib Drugs 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
229940102709 ferumoxytol Drugs 0.000 description 1
230000004927 fusion Effects 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
229950001109 galiximab Drugs 0.000 description 1
229950004896 ganitumab Drugs 0.000 description 1
229940063135 genotropin Drugs 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
108010013846 hematide Proteins 0.000 description 1
229940022353 herceptin Drugs 0.000 description 1
102000049885 human IL11 Human genes 0.000 description 1
102000053529 human TNFSF11 Human genes 0.000 description 1
229940045644 human calcitonin Drugs 0.000 description 1
229940065770 humatrope Drugs 0.000 description 1
229940048921 humira Drugs 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
UCNNJGDEJXIUCC-UHFFFAOYSA-L hydroxy(oxo)iron;iron Chemical compound [Fe].O[Fe]=O.O[Fe]=O UCNNJGDEJXIUCC-UHFFFAOYSA-L 0.000 description 1
230000003116 impacting effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
229940090438 infergen Drugs 0.000 description 1
229960000598 infliximab Drugs 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
230000003993 interaction Effects 0.000 description 1
229960003521 interferon alfa-2a Drugs 0.000 description 1
229960003358 interferon alfacon-1 Drugs 0.000 description 1
229960004461 interferon beta-1a Drugs 0.000 description 1
229960001388 interferon-beta Drugs 0.000 description 1
208000036971 interstitial lung disease 2 Diseases 0.000 description 1
229940032961 iron sucrose Drugs 0.000 description 1
229940054136 kineret Drugs 0.000 description 1
150000002605 large molecules Chemical class 0.000 description 1
229950010470 lerdelimumab Drugs 0.000 description 1
229940087875 leukine Drugs 0.000 description 1
239000003446 ligand Substances 0.000 description 1
229940076783 lucentis Drugs 0.000 description 1
KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
229960001046 methoxy polyethylene glycol-epoetin beta Drugs 0.000 description 1
229950000720 moxetumomab pasudotox Drugs 0.000 description 1
229960003816 muromonab-cd3 Drugs 0.000 description 1
230000035772 mutation Effects 0.000 description 1
ONDPWWDPQDCQNJ-UHFFFAOYSA-N n-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;phosphoric acid Chemical compound OP(O)(O)=O.OP(O)(O)=O.C=1C=C2C(C)(C)CNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 ONDPWWDPQDCQNJ-UHFFFAOYSA-N 0.000 description 1
229960005027 natalizumab Drugs 0.000 description 1
229940054205 natrecor Drugs 0.000 description 1
229960001267 nesiritide Drugs 0.000 description 1
HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 1
229940082926 neumega Drugs 0.000 description 1
239000002547 new drug Substances 0.000 description 1
229950010203 nimotuzumab Drugs 0.000 description 1
150000007523 nucleic acids Chemical group 0.000 description 1
229950005751 ocrelizumab Drugs 0.000 description 1
229960002450 ofatumumab Drugs 0.000 description 1
229950008516 olaratumab Drugs 0.000 description 1
229960000470 omalizumab Drugs 0.000 description 1
108010046821 oprelvekin Proteins 0.000 description 1
229960001840 oprelvekin Drugs 0.000 description 1
229950007283 oregovomab Drugs 0.000 description 1
229940035567 orencia Drugs 0.000 description 1
229940029358 orthoclone okt3 Drugs 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
229960000402 palivizumab Drugs 0.000 description 1
239000000199 parathyroid hormone Substances 0.000 description 1
229960001319 parathyroid hormone Drugs 0.000 description 1
108010048732 pegylated erythropoietin Proteins 0.000 description 1
229950003203 pexelizumab Drugs 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229940029359 procrit Drugs 0.000 description 1
229960003876 ranibizumab Drugs 0.000 description 1
230000009467 reduction Effects 0.000 description 1
229940116176 remicade Drugs 0.000 description 1
229940107685 reopro Drugs 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
229950003238 rilotumumab Drugs 0.000 description 1
229960004262 romiplostim Drugs 0.000 description 1
229950010968 romosozumab Drugs 0.000 description 1
WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 description 1
229940116949 sensipar Drugs 0.000 description 1
229940115586 simulect Drugs 0.000 description 1
239000000126 substance Substances 0.000 description 1
229940036185 synagis Drugs 0.000 description 1
229940120982 tarceva Drugs 0.000 description 1
230000002277 temperature effect Effects 0.000 description 1
229960000216 tenecteplase Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000012546 transfer Methods 0.000 description 1
229960000575 trastuzumab Drugs 0.000 description 1
108010075758 trebananib Proteins 0.000 description 1
229950001210 trebananib Drugs 0.000 description 1
229940079023 tysabri Drugs 0.000 description 1
229960003824 ustekinumab Drugs 0.000 description 1
229940099039 velcade Drugs 0.000 description 1
229950009578 vidupiprant Drugs 0.000 description 1
229950004393 visilizumab Drugs 0.000 description 1
229940099073 xolair Drugs 0.000 description 1
229950009002 zanolimumab Drugs 0.000 description 1
229940051223 zetia Drugs 0.000 description 1

Classifications

- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
- B65B3/003—Filling medical containers such as ampoules, vials, syringes or the like
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
- B65B3/04—Methods of, or means for, filling the material into the containers or receptacles
- B65B3/10—Methods of, or means for, filling the material into the containers or receptacles by application of pressure to material
- B65B3/12—Methods of, or means for, filling the material into the containers or receptacles by application of pressure to material mechanically, e.g. by pistons or pumps
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
- B65B3/26—Methods or devices for controlling the quantity of the material fed or filled
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
- B65B3/26—Methods or devices for controlling the quantity of the material fed or filled
- B65B3/28—Methods or devices for controlling the quantity of the material fed or filled by weighing

Landscapes

Engineering & Computer Science (AREA)
Mechanical Engineering (AREA)
Medical Preparation Storing Or Oral Administration Devices (AREA)
Basic Packing Technique (AREA)
Filling Of Jars Or Cans And Processes For Cleaning And Sealing Jars (AREA)

CA3217207A 2021-05-21 2022-05-19 Method of optimizing a filling recipe for a drug container Pending CA3217207A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US202163191797P	2021-05-21	2021-05-21
US63/191,797		2021-05-21
PCT/US2022/030014 WO2022246055A1 (en)	2021-05-21	2022-05-19	Method of optimizing a filling recipe for a drug container

Publications (1)

Publication Number	Publication Date
CA3217207A1 true CA3217207A1 (en)	2022-11-24

Family

ID=82100162

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA3217207A Pending CA3217207A1 (en)	2021-05-21	2022-05-19	Method of optimizing a filling recipe for a drug container

Country Status (11)

Country	Link
US (1)	US20240208680A1 (ko)
EP (1)	EP4341161A1 (ko)
JP (1)	JP2024523779A (ko)
KR (1)	KR20240011135A (ko)
CN (1)	CN117320964A (ko)
AU (1)	AU2022279223A1 (ko)
BR (1)	BR112023024278A2 (ko)
CA (1)	CA3217207A1 (ko)
IL (1)	IL307418A (ko)
MX (1)	MX2023013640A (ko)
WO (1)	WO2022246055A1 (ko)

Family Cites Families (155)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR850004274A (ko)	1983-12-13	1985-07-11	원본미기재	에리트로포이에틴의 제조방법
NZ210501A (en)	1983-12-13	1991-08-27	Kirin Amgen Inc	Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4703008A (en)	1983-12-13	1987-10-27	Kiren-Amgen, Inc.	DNA sequences encoding erythropoietin
WO1991005867A1 (en)	1989-10-13	1991-05-02	Amgen Inc.	Erythropoietin isoforms
US5856298A (en)	1989-10-13	1999-01-05	Amgen Inc.	Erythropoietin isoforms
US7217689B1 (en)	1989-10-13	2007-05-15	Amgen Inc.	Glycosylation analogs of erythropoietin
IL110669A (en)	1993-08-17	2008-11-26	Kirin Amgen Inc	Erythropoietin analogs
US6562596B1 (en)	1993-10-06	2003-05-13	Amgen Inc.	Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods
US5830851A (en)	1993-11-19	1998-11-03	Affymax Technologies N.V.	Methods of administering peptides that bind to the erythropoietin receptor
US5773569A (en)	1993-11-19	1998-06-30	Affymax Technologies N.V.	Compounds and peptides that bind to the erythropoietin receptor
US5885574A (en)	1994-07-26	1999-03-23	Amgen Inc.	Antibodies which activate an erythropoietin receptor
ATE306930T1 (de)	1994-08-12	2005-11-15	Immunomedics Inc	Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
US5686292A (en)	1995-06-02	1997-11-11	Genentech, Inc.	Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US5767078A (en)	1995-06-07	1998-06-16	Johnson; Dana L.	Agonist peptide dimers
US6753165B1 (en)	1999-01-14	2004-06-22	Bolder Biotechnology, Inc.	Methods for making proteins containing free cysteine residues
ATE375363T1 (de)	1997-07-14	2007-10-15	Bolder Biotechnology Inc	Derivate des wachstumshormons und verwandte proteine
PT986644E (pt)	1997-07-23	2007-01-31	Roche Diagnostics Gmbh	Preparação de eritropoietina por activação genética endógena com promotores virais
US6030086A (en)	1998-03-02	2000-02-29	Becton, Dickinson And Company	Flash tube reflector with arc guide
US6310078B1 (en)	1998-04-20	2001-10-30	Ortho-Mcneil Pharmaceutical, Inc.	Substituted amino acids as erythropoietin mimetics
US20050181482A1 (en)	2004-02-12	2005-08-18	Meade Harry M.	Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk
JP4087563B2 (ja)	1998-06-15	2008-05-21	ジーティーシーバイオセラピューティックスインコーポレイテッド	エリスロポエチン類似体−ヒト血清アルブミン融合物
AU773891C (en)	1998-10-23	2005-02-17	Kirin-Amgen Inc.	Dimeric thrombopoietin peptide mimetics binding to MP1 receptor and having thrombopoietic activity
CN1346369B (zh)	1998-10-23	2011-09-28	安姆根有限公司	用于预防和治疗贫血的方法以及组合物
DK1133558T4 (en)	1998-11-27	2016-05-17	Ucb Sa	Compositions and methods for increasing bone mineralization
EP1006184A1 (en)	1998-12-03	2000-06-07	F. Hoffmann-La Roche Ag	IGF-1 receptor interacting proteins (IIPs) genes coding therefor and uses thereof
EP1169352A4 (en)	1999-04-14	2005-05-04	Smithkline Beecham Corp	ANTIBODY AGAINST THE ERYTHROPOIETIN RECEPTOR
US7297680B2 (en)	1999-04-15	2007-11-20	Crucell Holland B.V.	Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
CZ299516B6 (cs)	1999-07-02	2008-08-20	F. Hoffmann-La Roche Ag	Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
JP2003512840A (ja)	1999-10-22	2003-04-08	ミレニアム・ファーマシューティカルズ・インコーポレイテッド	ラット脳に由来する核酸分子およびプログラム細胞死モデル
CA2391080A1 (en)	1999-11-12	2001-05-25	Merck Patent Gesellschaft Mit Beschraenkter Haftung	Erythropoietin forms with improved properties
US20050202538A1 (en)	1999-11-12	2005-09-15	Merck Patent Gmbh	Fc-erythropoietin fusion protein with improved pharmacokinetics
DE60107203T3 (de)	2000-01-21	2009-07-23	Biovex Ltd.	Herpes-virusstämme für die gentherapie
AUPQ599700A0 (en)	2000-03-03	2000-03-23	Super Internet Site System Pty Ltd	On-line geographical directory
US6586398B1 (en)	2000-04-07	2003-07-01	Amgen, Inc.	Chemically modified novel erythropoietin stimulating protein compositions and methods
AU5551601A (en)	2000-04-21	2001-11-07	Amgen Inc	Methods and compositions for the prevention and treatment of anemia
US6756480B2 (en)	2000-04-27	2004-06-29	Amgen Inc.	Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US7078376B1 (en)	2000-08-11	2006-07-18	Baxter Healthcare S.A.	Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
HUP0303854A2 (hu)	2000-09-08	2004-03-01	Gryhon Therapeutics, Inc.	Szintetikus erythropoiesis-stimuláló proteinek
US7271689B1 (en)	2000-11-22	2007-09-18	Fonar Corporation	Magnet structure
WO2002049673A2 (en)	2000-12-20	2002-06-27	F. Hoffmann-La Roche Ag	Conjugates of erythropoietin (pep) with polyethylene glycol (peg)
OA12589A (en)	2001-01-05	2006-06-08	Abgenix Inc	Antibodies to insulin-like growth factor i receptor.
WO2002085940A2 (en)	2001-04-04	2002-10-31	Genodyssee	New polynucleotides and polypeptides of the erythropoietin gene
MXPA03010210A (es)	2001-05-11	2004-03-10	Amgen Inc	Peptidos y moleculas relacionadas que se enlazan a tall-1.
ATE464068T1 (de)	2001-06-26	2010-04-15	Amgen Fremont Inc	Antikörper gegen opgl
US6900292B2 (en)	2001-08-17	2005-05-31	Lee-Hwei K. Sun	Fc fusion proteins of human erythropoietin with increased biological activities
US7247304B2 (en)	2001-08-23	2007-07-24	Genmab A/S	Methods of treating using anti-IL-15 antibodies
SI1425389T1 (sl)	2001-08-23	2012-02-29	Genmab As	Humana protitelesa, specifična za interlevkin 15 (IL-15)
US6930086B2 (en)	2001-09-25	2005-08-16	Hoffmann-La Roche Inc.	Diglycosylated erythropoietin
US7214660B2 (en)	2001-10-10	2007-05-08	Neose Technologies, Inc.	Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7138370B2 (en)	2001-10-11	2006-11-21	Amgen Inc.	Specific binding agents of human angiopoietin-2
US7521053B2 (en)	2001-10-11	2009-04-21	Amgen Inc.	Angiopoietin-2 specific binding agents
WO2003055526A2 (en)	2001-12-21	2003-07-10	Maxygen Aps	Erythropoietin conjugates
US7241444B2 (en)	2002-01-18	2007-07-10	Pierre Fabre Medicament	Anti-IGF-IR antibodies and uses thereof
DE60312639T2 (de)	2002-01-18	2007-11-29	Pierre Fabre Médicament	Antikörper gegen igf-ir und ihre verwendungen
GB0202252D0 (en)	2002-01-31	2002-03-20	Oxford Biomedica Ltd	Anemia
WO2003064664A1 (en)	2002-01-31	2003-08-07	Oxford Biomedica (Uk) Limited	Physiologically regulated erythropoietin- exprressing vector for the treatment of anaemia
DE60220451T2 (de)	2002-03-26	2008-01-24	Lek Pharmaceutical And Chemical Co. D.D.	Verfahren für die herstellung eines gewünschten profils von erythropoietin glyko-isoformen
EP1572079A4 (en)	2002-03-29	2006-09-06	Centocor Inc	MAMMAL-CDR MIMETIC BODIES, COMPOSITIONS, PROCESSES AND APPLICATION PURPOSES
ATE434662T1 (de)	2002-03-29	2009-07-15	Kumiai Chemical Industry Co	Acetolactatsynthase codierende gene
CA2485365A1 (en)	2002-05-13	2003-11-20	Modigenetech Ltd.	Ctp-extended erythropoietin
KR101086533B1 (ko)	2002-05-24	2011-11-23	쉐링 코포레이션	중화 사람 항-ｉｇｆｒ 항체, 이를 제조하는 방법 및 이를 포함하는 조성물
US8034904B2 (en)	2002-06-14	2011-10-11	Immunogen Inc.	Anti-IGF-I receptor antibody
US7538195B2 (en)	2002-06-14	2009-05-26	Immunogen Inc.	Anti-IGF-I receptor antibody
MXPA05000202A (es)	2002-06-28	2005-09-30	Johnson & Johnson	Cuerpos mimeicos ch1-deletados de epo de mimetica de mamifero.
WO2004002417A2 (en)	2002-06-28	2004-01-08	Centocor, Inc.	Mammalian ch1 deleted mimetibodies, compositions, methods and uses
WO2004009627A1 (en)	2002-07-19	2004-01-29	Cangene Corporation	Pegylated erythropoietic compounds
AU2003254950A1 (en)	2002-08-26	2004-03-11	Kirin Beer Kabushiki Kaisha	Peptides and drugs containing the same
EA033750B1 (ru)	2002-09-06	2019-11-21	Amgen Inc	Изолированная молекула нуклеиновой кислоты, кодирующая антитело человека к рецептору интерлейкина-1, и ее применение
IL166506A0 (en)	2002-09-11	2006-01-15	Fresenius Kabi De Gmbh	Hasylated polypeptides especially hasylated erythropoietin
US6919426B2 (en)	2002-09-19	2005-07-19	Amgen Inc.	Peptides and related molecules that modulate nerve growth factor activity
TWI320716B (en)	2002-10-14	2010-02-21	Abbott Lab	Erythropoietin receptor binding antibodies
US7396913B2 (en)	2002-10-14	2008-07-08	Abbott Laboratories	Erythropoietin receptor binding antibodies
US20040071694A1 (en)	2002-10-14	2004-04-15	Devries Peter J.	Erythropoietin receptor binding antibodies
WO2004034988A2 (en)	2002-10-16	2004-04-29	Amgen Inc.	Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors
US20040091961A1 (en)	2002-11-08	2004-05-13	Evans Glen A.	Enhanced variants of erythropoietin and methods of use
US7511012B2 (en)	2002-12-20	2009-03-31	Amgen Inc.	Myostatin binding agents
BRPI0408317A (pt)	2003-03-14	2006-03-07	Pharmacia Corp	anticorpos do receptor de igf-i para o tratamento de cáncer
WO2004087756A2 (en)	2003-04-02	2004-10-14	F. Hoffmann-La Roche Ag	Antibodies against insulin-like growth factor i receptor and uses thereof
US7220410B2 (en)	2003-04-18	2007-05-22	Galaxy Biotech, Llc	Monoclonal antibodies to hepatocyte growth factor
JP2007535895A (ja)	2003-05-01	2007-12-13	イムクローンシステムズインコーポレイティド	ヒトインシュリン様成長因子−１受容体に対する完全ヒト抗体
TWI353991B (en)	2003-05-06	2011-12-11	Syntonix Pharmaceuticals Inc	Immunoglobulin chimeric monomer-dimer hybrids
PT1625156E (pt)	2003-05-12	2013-01-09	Affymax Inc	Novos péptidos que se fixam ao receptor da eritropoietina
KR101163683B1 (ko)	2003-05-12	2012-07-10	아피맥스, 인크.	에리스로포이에틴 수용체에 결합하는 신규의 펩티드
KR20060028675A (ko)	2003-05-12	2006-03-31	아피맥스, 인크.	신규한 폴리 (에틸렌 글리콜) 개질 화합물 및 그의 용도
US7074755B2 (en)	2003-05-17	2006-07-11	Centocor, Inc.	Erythropoietin conjugate compounds with extended half-lives
KR20060032140A (ko)	2003-05-30	2006-04-14	센토코 인코포레이티드	트랜스글루타미나아제를 이용한 신규 에리트로포이에틴접합체의 형성
US20050037390A1 (en)	2003-06-04	2005-02-17	Irm Llc, A Delaware Limited Liability Company	Methods and compositions for modulating erythropoietin expression
AR046071A1 (es)	2003-07-10	2005-11-23	Hoffmann La Roche	Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
MEP31508A (en)	2003-07-15	2010-10-10	Amgen Inc	Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
CN103880955A (zh)	2003-07-18	2014-06-25	安姆根有限公司	肝细胞生长因子的特异性结合物
US20050019914A1 (en)	2003-07-24	2005-01-27	Aventis Pharma Deutschland Gmbh	Perfusion process for producing erythropoietin
GB0317511D0 (en)	2003-07-25	2003-08-27	Biovex Ltd	Viral vectors
WO2005021579A2 (en)	2003-08-28	2005-03-10	Biorexis Pharmaceutical Corporation	Epo mimetic peptides and fusion proteins
CN1882355A (zh)	2003-09-09	2006-12-20	沃伦药品公司	保持内源性*组织保护活性的长效*
WO2005081687A2 (en)	2003-09-30	2005-09-09	Centocor, Inc.	Human hinge core mimetibodies, compositions, methods and uses
UA89481C2 (uk)	2003-09-30	2010-02-10	Центокор, Инк.	Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
JP4931597B2 (ja)	2003-11-07	2012-05-16	イミュネックス・コーポレーション	インターロイキン−４受容体を結合する抗体
PE20050928A1 (es)	2003-11-21	2005-11-08	Schering Corp	Combinaciones terapeuticas de anticuerpo anti-igfr1
AU2004293103C1 (en)	2003-11-24	2010-12-02	Ratiopharm Gmbh	Glycopegylated erythropoietin
US8633157B2 (en)	2003-11-24	2014-01-21	Novo Nordisk A/S	Glycopegylated erythropoietin
WO2005058967A2 (en)	2003-12-16	2005-06-30	Pierre Fabre Medicament	Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof
EP1548031A1 (en)	2003-12-22	2005-06-29	Dubai Genetics FZ-LLC	Nature-identical erythropoietin
JP2008500275A (ja)	2003-12-31	2008-01-10	セントカー・インコーポレーテツド	Ｎ末端の遊離チオールを有する新規な組み換えタンパク質
DK1699821T3 (da)	2003-12-31	2012-07-16	Merck Patent Gmbh	Fc-ERYTHROPOIETIN-FUSIONSPROTEIN MED FORBEDREDE FARMAKOKINETIKKER
US7423139B2 (en)	2004-01-20	2008-09-09	Insight Biopharmaceuticals Ltd.	High level expression of recombinant human erythropoietin having a modified 5′-UTR
US20050187158A1 (en)	2004-01-22	2005-08-25	Ranby Mats G.	Pharmaceutical composition
WO2005084711A1 (fr)	2004-03-02	2005-09-15	Chengdu Institute Of Biological Products	Erythropoietine recombinante pegylee a activite in vivo
WO2005092369A2 (en)	2004-03-11	2005-10-06	Fresenius Kabi Deutschland Gmbh	Conjugates of hydroxyethyl starch and erythropoietin
EP1740208A2 (en)	2004-03-23	2007-01-10	Amgen, Inc	Monoclonal antibodies specific for human ox40l (cd134l)
US20050227289A1 (en)	2004-04-09	2005-10-13	Reilly Edward B	Antibodies to erythropoietin receptor and uses thereof
AU2005235794A1 (en)	2004-04-23	2005-11-03	Cambridge Antibody Technology Limited	Erythropoietin protein variants
DE602005014117D1 (de)	2004-07-07	2009-06-04	Lundbeck As Valby H	Neues carbamyliertes epo und verfahren zu dessen herstellung
FR2873699B1 (fr)	2004-07-29	2009-08-21	Pierre Fabre Medicament Sa	Nouveaux anticorps anti igf ir rt leurs utilisations
WO2006029094A2 (en)	2004-09-02	2006-03-16	Xencor, Inc.	Erythropoietin derivatives with altered immunogenicity
KR20070092706A (ko)	2004-11-10	2007-09-13	아플라겐 게엠베하	조혈을 촉진하는 분자
MY146381A (en)	2004-12-22	2012-08-15	Amgen Inc	Compositions and methods relating relating to anti-igf-1 receptor antibodies
CA2589860A1 (en)	2005-01-24	2006-08-03	Amgen Inc.	Humanized anti-amyloid antibody
US7592429B2 (en)	2005-05-03	2009-09-22	Ucb Sa	Sclerostin-binding antibody
EP2100614B8 (en)	2005-06-17	2013-11-20	ImClone LLC	Antibody against PDGFR-alpha for use in the treatment of tumours
WO2007000328A1 (en)	2005-06-27	2007-01-04	Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa	Antibodies that bind to an epitope on insulin-like growth factor 1 receptor and uses thereof
EP2397498A3 (en)	2005-07-18	2013-11-27	Amgen, Inc	Human anti-B7RP1 neutralizing antibodies
FR2888850B1 (fr)	2005-07-22	2013-01-11	Pf Medicament	Nouveaux anticorps anti-igf-ir et leurs applications
PE20071101A1 (es)	2005-08-31	2007-12-21	Amgen Inc	Polipeptidos y anticuerpos
GB0603683D0 (en)	2006-02-23	2006-04-05	Novartis Ag	Organic compounds
TWI395754B (zh)	2006-04-24	2013-05-11	Amgen Inc	人類化之ｃ-ｋｉｔ抗體
EP2032600A2 (en)	2006-05-19	2009-03-11	Glycofi, Inc.	Erythropoietin compositions
CL2007002567A1 (es)	2006-09-08	2008-02-01	Amgen Inc	Proteinas aisladas de enlace a activina a humana.
EP2106261A4 (en)	2006-11-07	2010-05-26	Merck Sharp & Dohme	ANTAGONISTS OF PCSK9
CA2669424A1 (en)	2006-11-07	2008-05-29	Merck & Co., Inc.	Antagonists of pcsk9
US20100040611A1 (en)	2006-11-07	2010-02-18	Sparrow Carl P	Antagonists of pcsk9
EP2083860A4 (en)	2006-11-07	2010-05-26	Merck Sharp & Dohme	PCSK9 ANTAGONISTS
US8232372B2 (en)	2006-12-14	2012-07-31	Schering Corp.	Engineered anti-TSLP antibody
WO2008125623A2 (en)	2007-04-13	2008-10-23	Novartis Ag	Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (pcsk9)
EA201000006A1 (ru)	2007-06-20	2010-10-29	Айрм Ллк	Способы и композиции для лечения аллергических заболеваний
US7982016B2 (en)	2007-09-10	2011-07-19	Amgen Inc.	Antigen binding proteins capable of binding thymic stromal lymphopoietin
BRPI0818765A8 (pt)	2007-10-26	2016-02-10	Schering Corp	Polipeptídeo, anticorpo ou seu fragmento de ligação de antígeno, polinucleotídeo, célula hospedeira, vetor, composição, uso e método para produzir polipeptídeo
AR070316A1 (es)	2008-02-07	2010-03-31	Merck & Co Inc	Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
AR070315A1 (es)	2008-02-07	2010-03-31	Merck & Co Inc	Anticuerpos 1b20 antagonistas de pcsk9
TWI445716B (zh)	2008-09-12	2014-07-21	Rinat Neuroscience Corp	Ｐｃｓｋ９拮抗劑類
JO3672B1 (ar)	2008-12-15	2020-08-27	Regeneron Pharma	أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
JO3382B1 (ar)	2008-12-23	2019-03-13	Amgen Inc	أجسام مضادة ترتبط مع مستقبل cgrp بشري
WO2011037791A1 (en)	2009-09-25	2011-03-31	Merck Sharp & Dohme Corp.	Antagonists of pcsk9
WO2011053783A2 (en)	2009-10-30	2011-05-05	Merck Sharp & Dohme Corp.	Ax213 and ax132 pcsk9 antagonists and variants
WO2011053759A1 (en)	2009-10-30	2011-05-05	Merck Sharp & Dohme Corp.	Ax1 and ax189 pcsk9 antagonists and variants
AR079336A1 (es)	2009-12-11	2012-01-18	Irm Llc	Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
EP2545079A2 (en)	2010-03-11	2013-01-16	Rinat Neuroscience Corporation	ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
WO2012054438A1 (en)	2010-10-22	2012-04-26	Schering Corporation	Anti-pcsk9
MX2013007168A (es)	2010-12-22	2013-11-04	Genentech Inc	Anticuerpo anti-pcsk9 y metodos de uso.
CA2825838C (en)	2011-01-28	2020-10-27	Sanofi	Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
EA201391157A1 (ru)	2011-02-11	2014-02-28	АйАрЭм ЭлЭлСи	Антагонисты pcsk9
JOP20200043A1 (ar)	2011-05-10	2017-06-16	Amgen Inc	طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US10684303B2 (en) *	2011-07-22	2020-06-16	Vanrx Pharmasystems Inc.	Method for protecting and unprotecting the fluid path in a controlled environment enclosure
ES2875957T3 (es)	2012-12-20	2021-11-11	Amgen Inc	Agonistas del receptor APJ y usos de los mismos
KR102258564B1 (ko)	2013-03-14	2021-05-28	암젠 인크	메탈로프로테이나제 타입 3의 조직 억제제(timp-3)의 변이체, 조성물 및 방법
US20140274874A1 (en)	2013-03-14	2014-09-18	Amgen Inc.	Variants of tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods

2022
- 2022-05-19 KR KR1020237038066A patent/KR20240011135A/ko unknown
- 2022-05-19 WO PCT/US2022/030014 patent/WO2022246055A1/en active Application Filing
- 2022-05-19 CN CN202280035596.1A patent/CN117320964A/zh active Pending
- 2022-05-19 AU AU2022279223A patent/AU2022279223A1/en active Pending
- 2022-05-19 IL IL307418A patent/IL307418A/en unknown
- 2022-05-19 MX MX2023013640A patent/MX2023013640A/es unknown
- 2022-05-19 JP JP2023569877A patent/JP2024523779A/ja active Pending
- 2022-05-19 EP EP22731368.1A patent/EP4341161A1/en active Pending
- 2022-05-19 BR BR112023024278A patent/BR112023024278A2/pt unknown
- 2022-05-19 US US18/288,549 patent/US20240208680A1/en active Pending
- 2022-05-19 CA CA3217207A patent/CA3217207A1/en active Pending

Also Published As

Publication number	Publication date
KR20240011135A (ko)	2024-01-25
BR112023024278A2 (pt)	2024-01-30
US20240208680A1 (en)	2024-06-27
CN117320964A (zh)	2023-12-29
WO2022246055A1 (en)	2022-11-24
AU2022279223A1 (en)	2023-10-19
EP4341161A1 (en)	2024-03-27
MX2023013640A (es)	2023-11-30
IL307418A (en)	2023-12-01
JP2024523779A (ja)	2024-07-02

Publication	Publication Date	Title
US20210361869A1 (en)	2021-11-25	Injector and method of assembly
US11305056B2 (en)	2022-04-19	Needle insertion-retraction system having dual torsion spring system
US11957883B2 (en)	2024-04-16	Plunger rod and syringe assembly system and method
US11285266B2 (en)	2022-03-29	Drug delivery device having minimized risk of component fracture upon impact events
CA3052482A1 (en)	2018-09-13	Needle insertion by overpressure
AU2018220071A1 (en)	2018-09-06	Drug Delivery Device
US20210346596A1 (en)	2021-11-11	Platform assembly process for drug delivery device
US20210228797A1 (en)	2021-07-29	Fluid path assembly for a drug delivery device
JP7510952B2 (ja)	2024-07-04	シリンジ滅菌確認アセンブリ及び方法
US20240208680A1 (en)	2024-06-27	Method of optimizing a filling recipe for a drug container
US20220031939A1 (en)	2022-02-03	Drug delivery devices with partial drug delivery member retraction
CA3170808A1 (en)	2021-09-23	Controlled dispense syringe
US11213620B2 (en)	2022-01-04	Drug delivery devices with partial drug delivery member retraction